InspireMD, Inc. (NYSE:NSPR - Get Free Report) insider Shane Thomas Gleason sold 8,411 shares of the company's stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $1.57, for a total value of $13,205.27. Following the completion of the sale, the insider directly owned 1,166,253 shares of the company's stock, valued at approximately $1,831,017.21. This trade represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shane Thomas Gleason also recently made the following trade(s):
- On Monday, February 2nd, Shane Thomas Gleason sold 2,000 shares of InspireMD stock. The stock was sold at an average price of $1.60, for a total value of $3,200.00.
- On Friday, January 30th, Shane Thomas Gleason sold 2,900 shares of InspireMD stock. The shares were sold at an average price of $1.63, for a total value of $4,727.00.
- On Thursday, January 29th, Shane Thomas Gleason sold 5,000 shares of InspireMD stock. The shares were sold at an average price of $1.65, for a total value of $8,250.00.
- On Wednesday, January 28th, Shane Thomas Gleason sold 12,395 shares of InspireMD stock. The shares were sold at an average price of $1.65, for a total transaction of $20,451.75.
- On Tuesday, January 27th, Shane Thomas Gleason sold 4,781 shares of InspireMD stock. The shares were sold at an average price of $1.66, for a total transaction of $7,936.46.
- On Wednesday, January 21st, Shane Thomas Gleason sold 17,593 shares of InspireMD stock. The stock was sold at an average price of $1.62, for a total transaction of $28,500.66.
- On Tuesday, January 20th, Shane Thomas Gleason sold 2,955 shares of InspireMD stock. The stock was sold at an average price of $1.59, for a total transaction of $4,698.45.
- On Friday, January 16th, Shane Thomas Gleason sold 2,250 shares of InspireMD stock. The shares were sold at an average price of $1.61, for a total transaction of $3,622.50.
- On Thursday, January 15th, Shane Thomas Gleason sold 2,909 shares of InspireMD stock. The stock was sold at an average price of $1.58, for a total transaction of $4,596.22.
InspireMD Stock Up 3.2%
NYSE NSPR opened at $1.63 on Tuesday. The firm has a market cap of $69.06 million, a P/E ratio of -2.17 and a beta of 0.72. InspireMD, Inc. has a 52-week low of $1.51 and a 52-week high of $3.80. The business's 50-day moving average price is $1.83 and its 200 day moving average price is $2.16.
Institutional Trading of InspireMD
A number of institutional investors have recently modified their holdings of the business. Rosalind Advisors Inc. raised its position in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company's stock worth $9,413,000 after acquiring an additional 1,616,644 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company's stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the period. Aberdeen Group plc boosted its holdings in InspireMD by 27.9% during the fourth quarter. Aberdeen Group plc now owns 3,173,364 shares of the company's stock worth $5,649,000 after buying an additional 692,247 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company's stock worth $5,882,000 after buying an additional 1,205,328 shares during the period. Finally, Velan Capital Investment Management LP increased its holdings in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company's stock valued at $5,166,000 after buying an additional 1,239,669 shares in the last quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting InspireMD
Here are the key news stories impacting InspireMD this week:
- Positive Sentiment: Maxim Group initiated coverage with a "Buy" rating and a $6.00 price target (roughly +268% from the current ~ $1.63 price), which likely drove investor interest and the intraday uptick. Article Title
- Negative Sentiment: Insider Shane Thomas Gleason has sold a series of shares across mid‑January to early February (multiple filings) — a total of 61,194 shares sold between Jan. 15 and Feb. 2 at prices roughly in the $1.57–$1.66 range. While the insider still holds ~1.14M shares (valued at ~ $1.8M), the concentrated string of sales is a negative signal that may cap gains or increase short‑term volatility. SEC Filing
Analyst Upgrades and Downgrades
Separately, Maxim Group initiated coverage on shares of InspireMD in a research note on Monday. They issued a "buy" rating and a $6.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $5.00.
Read Our Latest Stock Analysis on NSPR
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
